12 Month Price Forecast For CLRB
Distance to CLRB Price Forecasts
CLRB Price Momentum
🤔 Considering Cellectar (CLRB)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: December 13, 2024 10:02 AM UTC
CLRB Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, CLRB has a consensus that is bullish. The median price target is $12.50, with forecasts ranging from $7.00 to $21.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CLRB currently trading at $0.26, the median price forecast suggests a 4,707.7% upside. The most optimistic forecast comes from at , projecting a 7,976.9% upside, while at provides the most conservative target, suggesting a 2,592.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLRB Analyst Consensus
CLRB Price Target Range
Latest CLRB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLRB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 19, 2024 | Oppenheimer | Jeff Jones | Outperform | Maintains | $12.00 |
| Oct 11, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $14.00 |
| Mar 28, 2024 | Oppenheimer | Jeff Jones | Outperform | Reiterates | $12.00 |
| Mar 28, 2024 | Roth MKM | Jonathan Aschoff | Buy | Maintains | $28.00 |
| Mar 4, 2024 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $20.00 |
| Nov 4, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $4.00 |
| Jul 18, 2022 | Oppenheimer | Jeff Jones | Outperform | Assumes | $5.50 |
| Nov 25, 2020 | Ladenburg Thalmann | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Brookline Capital | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Maxim Group | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Roth Capital | Buy | Initiates | $0.00 | |
| Nov 25, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Jul 1, 2020 | Oppenheimer | Outperform | Initiates | $0.00 | |
| Jun 23, 2020 | Maxim Group | Buy | Initiates | $0.00 | |
| Sep 13, 2019 | Roth Capital | Buy | Initiates | $0.00 | |
| Jul 30, 2019 | Brookline Capital | Buy | Initiates | $0.00 | |
| May 2, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 | |
| Dec 21, 2016 | Ladenburg Thalmann | Buy | Initiates | $0.00 |
Cellectar Biosciences Inc (CLRB) Financial Data
Cellectar Biosciences Inc has a market capitalization of $52.83M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -796.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Cellectar Biosciences Inc (CLRB) Company Overview
About Cellectar Biosciences Inc
Develops cancer treatment drugs.
The company focuses on the discovery, development, and commercialization of biopharmaceuticals specifically for cancer treatment. It generates revenue through its clinical drug candidates, particularly its lead product CLR 131, which is undergoing multiple clinical studies for various types of cancer. Additionally, collaborations with other firms enhance its development capabilities and market reach.
Founded in 2002 and based in Florham Park, New Jersey, Cellectar Biosciences is advancing its drug pipeline with a focus on phospholipid drug conjugates. Its partnerships with organizations like Orano Med and LegoChemBio indicate a strategic approach to expand its research and development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
20
CEO
Mr. James V. Caruso
Country
United States
IPO Year
2005
Website
www.cellectar.comCellectar Biosciences Inc (CLRB) Latest News & Analysis
Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options
2 days agoCellectar Biosciences, Inc. (CLRB) announced a strategic update on its clinical development programs for its phospholipid ether drug conjugate platform targeting cancer.
Cellectar's update on its cancer drug platform could signal progress in clinical trials, potentially impacting stock value and investor confidence in the company's growth prospects.
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
3 days agoiopofosine I 131 is in late-stage clinical development, showing promising Phase 2 results and presenting a significant market opportunity for investors.
Strong Phase 2 data and a substantial market opportunity for iopofosine I-131 signal potential for future revenue growth, influencing investment decisions and stock valuations.
NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225)
22 days agoNorthStar Medical Radioisotopes signed a Master Supply Agreement with Cellectar Biosciences to integrate Ac-225 into Cellectar's PLE platform, enhancing radiotherapeutic production capabilities.
The agreement enhances Cellectar's product offerings in radiotherapy, potentially increasing revenue and market competitiveness, which could positively impact its stock performance.
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
25 days agoCellectar Biosciences, Inc. (NASDAQ: CLRB) will hold its Q3 2024 earnings conference call on November 18, 2024, at 8:30 AM ET, featuring key company executives.
Cellectar's upcoming earnings call could reveal key financial health indicators and strategic plans, impacting stock performance and investor sentiment.
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
25 days agoPhase 2 CLOVER-WaM pivotal study data will be presented orally at the 66th Annual American Society of Hematology Meeting and Exposition.
The oral presentation of Phase 2 CLOVER-WaM study data could indicate promising developments in treatment options, potentially impacting the stock performance of related biotech companies.
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
29 days agoNorthStar will supply Cellectar with non-carrier-added Ac-225 for its clinical programs, potentially enhancing Cellectar's product offerings.
Cellectar's access to non-carrier-added Ac-225 enhances its clinical potential, potentially driving growth and increasing market competitiveness, influencing investor sentiment positively.
Frequently Asked Questions About CLRB Stock
What is Cellectar Biosciences Inc's (CLRB) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Cellectar Biosciences Inc (CLRB) has a median price target of $12.50. The highest price target is $21.00 and the lowest is $7.00.
Is CLRB stock a good investment in 2025?
According to current analyst ratings, CLRB has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CLRB stock?
Wall Street analysts predict CLRB stock could reach $12.50 in the next 12 months. This represents a 4,707.7% increase from the current price of $0.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cellectar Biosciences Inc's business model?
The company focuses on the discovery, development, and commercialization of biopharmaceuticals specifically for cancer treatment. It generates revenue through its clinical drug candidates, particularly its lead product CLR 131, which is undergoing multiple clinical studies for various types of cancer. Additionally, collaborations with other firms enhance its development capabilities and market reach.
What is the highest forecasted price for CLRB Cellectar Biosciences Inc?
The highest price target for CLRB is $21.00 from at , which represents a 7,976.9% increase from the current price of $0.26.
What is the lowest forecasted price for CLRB Cellectar Biosciences Inc?
The lowest price target for CLRB is $7.00 from at , which represents a 2,592.3% increase from the current price of $0.26.
What is the overall CLRB consensus from analysts for Cellectar Biosciences Inc?
The overall analyst consensus for CLRB is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.50.
How accurate are CLRB stock price projections?
Stock price projections, including those for Cellectar Biosciences Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
